Abstract:

Objective    To investigate expression of HMGB1 (high mobility group box1) in human endometrial adenocarcinoma and ECC-1, HEC-1-a and KLE cells, and explore its relation with the clinical characteristic. Methods     Immunohistochemical staining was used to detect expression of HMGB1 in 45 atypical hyperplasia endometria, 120 endometrial adenocarcinomas and 20 normal endometria, and Western blot was applied to analyze expression of HMGB1. Expression of HMGB1 was also detected in high, moderate and low grade endometrial adenocarcinoma cells (ECC-1, HEC-1-a and KLE) by immunohistochemistry and Western blot. Results     Positive expression rates of HMGB1 were 80.00% (96/120) and 66.67% (30/45) in endometrial adenocarcinoma and atypical hyperplasia endometria, respectively, which were significantly higher than 5.00% (1/20) in normal endometria. The positive expression rate of HMGB1 was significantly correlated with invasion, metastasis and operative-pathological staging of human endometrial adenocarcinoma (P＜0.05), while it showed no significant correlation with the grade (P＞0.05). Expression of HMGB1 was positive in ECC1, HEC-1-a and KLE cells with immunohistochemistry and Western blot, while the difference in expression level was not significant. Conclusion     Over-expression of HMGB1 may play an important role in carcinogenesis and development of endometrial adenocarcinoma.

Key words: Endometrial neoplasms； Adenocarcinoma; High mobility group box 1; Immunohistochemistry; Western blot